MX2009003127A - Vacunas contra infeccion por clamidia. - Google Patents

Vacunas contra infeccion por clamidia.

Info

Publication number
MX2009003127A
MX2009003127A MX2009003127A MX2009003127A MX2009003127A MX 2009003127 A MX2009003127 A MX 2009003127A MX 2009003127 A MX2009003127 A MX 2009003127A MX 2009003127 A MX2009003127 A MX 2009003127A MX 2009003127 A MX2009003127 A MX 2009003127A
Authority
MX
Mexico
Prior art keywords
vaccines against
chlamydial infection
against chlamydial
proteins
chlamydia trachomatis
Prior art date
Application number
MX2009003127A
Other languages
English (en)
Inventor
Yves Lobet
Mark Alderson
Pascal Mettens
Peter Probst
Steven Reed
Rhea Coler
Jean Francois L Maisonneuve
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2009003127A publication Critical patent/MX2009003127A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para el tratamiento o prevención de infección de Chlamydia trachomatis ocular mediante la administración de una cantidad segura y efectiva de una composición inmunogénica que comprende una o más proteínas de Chlamydia trachomatis, fragmentos inmunogénicos de las mismas o polinucleótidos que codifican las proteínas o fragmentos, seleccionadas de la lista que consiste en Swib, Momp, Ct-858, Ct-875, Ct-622, Ct-089, dominio pasajero de PmpG (PmpGpd) y dominio pasajero de PmpD (PmpDpd).
MX2009003127A 2006-10-04 2007-10-03 Vacunas contra infeccion por clamidia. MX2009003127A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82809206P 2006-10-04 2006-10-04
PCT/EP2007/060500 WO2008040757A1 (en) 2006-10-04 2007-10-03 Vaccines against chlamydial infection

Publications (1)

Publication Number Publication Date
MX2009003127A true MX2009003127A (es) 2009-06-26

Family

ID=39092594

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003127A MX2009003127A (es) 2006-10-04 2007-10-03 Vacunas contra infeccion por clamidia.

Country Status (11)

Country Link
US (1) US20100172927A1 (es)
EP (1) EP2068916A1 (es)
JP (1) JP2010505795A (es)
KR (1) KR20090077065A (es)
CN (1) CN101522215A (es)
AU (1) AU2007304199A1 (es)
BR (1) BRPI0719169A2 (es)
CA (1) CA2664236A1 (es)
EA (1) EA200900338A1 (es)
MX (1) MX2009003127A (es)
WO (1) WO2008040757A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
ES2788728T3 (es) 2010-05-28 2020-10-22 Spixia Biotechnology Ab Antígeno de la MOMP quimérica, método y uso
US10675339B2 (en) * 2014-11-21 2020-06-09 Merck Sharp & Dohme Corp. Recombinant expression of Chlamydia MOMP antigen
CN104800841B (zh) * 2015-03-02 2019-04-02 中国农业科学院兰州兽医研究所 牦牛流产衣原体灭活疫苗及其制备方法
CN111735967B (zh) * 2020-08-03 2020-12-22 天津中逸安健生物科技有限公司 一种重组新型冠状病毒疫苗吸附完全性检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034483A2 (en) * 1998-12-08 2000-06-15 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
NZ546711A (en) * 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease

Also Published As

Publication number Publication date
EA200900338A1 (ru) 2009-10-30
CA2664236A1 (en) 2008-04-10
BRPI0719169A2 (pt) 2014-02-04
JP2010505795A (ja) 2010-02-25
WO2008040757A1 (en) 2008-04-10
AU2007304199A1 (en) 2008-04-10
EP2068916A1 (en) 2009-06-17
CN101522215A (zh) 2009-09-02
US20100172927A1 (en) 2010-07-08
KR20090077065A (ko) 2009-07-14

Similar Documents

Publication Publication Date Title
MX2009003127A (es) Vacunas contra infeccion por clamidia.
UA97943C2 (ru) Вакцина против инфекции chlamydia
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
FR10C0043I1 (fr) Solubilisation de polysaccharides capsulaires
UA100507C2 (ru) Предупреждение и лечение субклинической формы болезней, вызываемых цирковирусом свиней (pcvd)
IL227934A (en) An immunogenic preparation containing polysaccharide or oligosaccharide from s. type 5 or 8 aureus and various aspects related to it
WO2008071898A3 (fr) Appareil de traitement par emission de flashs lumineux avec dispositif d'anti-eblouissement
WO2010018408A3 (en) Pharmaceutical compositions with tetrabenazine
WO2011019956A3 (en) Pharmaceutical compositions with tetrabenazine
MXPA06005639A (es) Adyuvante antimicrobiano.
WO2007030810A3 (en) Multiparameter whole blood monitor and method
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2008029367A3 (en) Shapeable pad
WO2007120817A3 (en) Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
WO2010100632A3 (en) Chlamydia antigens
WO2008112390A3 (en) Terpolymers for controlled release of bioactive agents from implantable medical devices
BRPI0612005A2 (pt) agente profilático ou terapêutico, composição oftalmológica, uso de selenoproteína p, e, método de prevenção/tratamento de uma doença corneal/conjuntival
WO2008070356A3 (en) Block biodegradable copolymers for medical devices
JP2010505795A5 (es)
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
BRPI0910884A2 (pt) composição imunogênica, método para tratar ou prevenir infecção ou doença estafilocócicas, e, uso de uma composição imunogênica.
WO2007082105A3 (en) Chlamydia vaccine
EP1937711A4 (en) EPITOPES, COMBINED EPITOPES, USE OF EPITOPES OR COMBINATIONS THEREOF, COMPOSITION, USE OF THE COMPOSITION, PROPHYLACTIC ANTI-HIV-I VACCINES, THERAPEUTIC VACCINES, METHOD FOR IDENTIFYING EPITOPES AND METHODS OF TREATMENT AND PREVENTION
WO2005034879A3 (en) Treatment of diseases involving erbb2 kinase overexpression

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal